Insurance

Will the New Cancer Drug Change Affect Me?

How can iFAST Digital Term help you with the upcoming changes?

  • Tham Guo Liang
  • |
  • Published on 21 Mar 2023

The No.1 killer in Singapore: Cancer

Whenever you ask someone to name one critical illness condition, Cancer is often the one that comes to everyone's mind.

According to the latest data published by the Ministry of Health, Cancer accounts for 26.4% of the total deaths in Singapore for the year 20211. Cancer is also the number one killer in Singapore for the past few years.

Cancer treatments are definitely not cheap and often stretches over a long period of time. Many of us choose to purchase insurance so as to defray some of the potential hefty medical bills should one be diagnosed with cancer.


Upcoming outpatient cancer drug treatment changes

Many of us have purchased Integrated Shield Plans (IP) to further enhance our coverage against high medical costs.

Cancer being the number one killer has led to the rise in the cost of cancer treatments. To better sustain the rise in costs, the Ministry of Health (MOH) have announced a newly created Cancer Drug List (CDL).

This new change would mean that usage of MediShield Life and IP to reimburse outpatient cancer drug treatments will be restricted to the drugs included in the CDL only. As of 1 September 2022, more than 90% of cancer drugs that are approved by the Health Science Authority (HSA) are on the list.


Changes to MediShield Life

For MediShield Life, these changes are already effective from September 2022. There will be separate limits for cancer drug treatments and cancer drug services.


Changes to Integrated Shield Plan (Private Hospital Insurance)

For those with IPs, insurers will no longer be able to provide coverage for drugs and treatments not on the CDL from April 2023 if you do not have additional riders.


How am I affected?

Everyone is affected, even if you are holding on to the highest plan tier your IP insurer can offer you. The worry for everyone now is that what would happen if your treatment goes beyond that of the CDL?

With this new change, what it means is that you may have to fork out the treatment cost at your own expense if you are prescribed with a drug that is not in the CDL.

There is also a possibility that you will require multiple drugs from the CDL in a month. This will mean that you will only be able to claim up to the highest limit between the multiple drugs (not combine limits of the drugs) used since each drug will have their own limits.

The question will then be, should you tell your doctor to not administer a drug just because it is not covered or just stick to one drug?

We strongly do not encourage doing so because seeking treatment should be your upmost priority. Instead, you should check with your doctor whether there is alternative treatment.

The point here is, we should always give ourself assurance against the worst-case scenario. In this case it could be high medical bills at our own expenses.


Introducing iFAST Digital Term

When we first heard about the upcoming change, we immediately reached out to our insurance partner (Raffles Health Insurance) and insisted that our cancer riders must be on a basis where full pay-out is given upon diagnosis.

Furthermore, our product is created with the intention of providing protection coverage. Premiums are kept affordable as there is no investment element in this plan.


How our Cancer360 rider can help

While your MediShield Life and Integrated Shield plans are meant to reimburse your hospitalisation and/or medical costs, these plans will offer limited coverage for drugs and treatments that are not on MOH's CDL. This is where our Cancer360 rider can help to reassure you as a lump sum pay-out is given in the event of a cancer diagnosis. There are no restrictions on how you may use this Cancer360 pay-out, and your pay-out can be used to help alleviate your cost of drugs and treatments that are not on the CDL.

Our riders are also offered on an additional sum assured basis. This means that whenever our clients make a claim on any one of the cancer riders, it will not reduce the death sum assured of the core plan. Your death coverage remains intact. This way, you will receive a lump sum of money for any treatment cost that might potentially come your way. Our product is designed to provide assurance to our clients at a time when you need it most. We want you to focus on getting treatment rather than worrying about whether or not you can afford the treatment.

You may find more details on our cancer riders below:

When it comes to your personal health being, let's not take a gamble on whether you will be diagnosed. Instead, give yourself the assurance today so that you don't have to worry when you are diagnosed.

Plan early and consider getting a cancer cover to enhance your insurance coverage now!


Get a Quote >


Or click here if you would like to speak to us


Available Products on FSMOne Insurance

Term Life, Whole Life, Critical Illness, Annuity, Health, Endowment, General Insurance (Personal and Commercial)


from AIG, Allianz, Chubb, Etiqa Insurance, FWD Insurance, Great Eastern, Manulife, NTUC Income, QBE, Sompo and Tokio Marine Life Insurance


*Please check with our advisory team if the product you want is available on FSMOne Insurance


You may also be interested in...

iFAST Digital Term – *NEW* on FSMOne.com

Insurance Rebate Program – Save more when you insure with us

This is why you should Buy Term Invest the Rest (BTIR)

Best Personal Accident Insurance Singapore

Should I switch from Eldershield to CareShield Life?


Source:

1https://www.moh.gov.sg/resources-statistics/singapore-health-facts/principal-causes-of-death

2https://www.moh.gov.sg/news-highlights/details/higher-medishield-life-claim-limit-for-cancer-drug-services

All materials and contents found in this site are strictly for general circulation and informational purposes only and should not be considered as an offer, or solicitation, to deal in any of the funds or products found/identified in this site. While iFAST Financial Pte Ltd ("IFPL") has tried to provide accurate and timely information, there may be inadvertent delays, omissions, technical or factual inaccuracies and typographical errors. Any opinion or estimate contained in this report is made on a general basis and neither IFPL nor any of its servants or agents have given any consideration to nor have they or any of them made any investigation of the investment objective, financial situation or particular need of any user or reader, any specific person or group of persons. You should consider carefully if the products you are going to purchase are suitable for your investment objective, investment experience, risk tolerance and other personal circumstances. If you are uncertain about the suitability of the investment product, please seek advice from a financial adviser, before making a decision to purchase the investment product. Past performance is not indicative of future performance. The value of the investment products and the income from them may fall as well as rise. Opinions expressed herein are subject to change without notice. In respect of any matters arising from, or in connection with the said research analyses or research reports, recipients of the report are to contact IFPL at 10 Collyer Quay, #26-01 Ocean Financial Centre Building, Singapore 049315, or by telephone at +65 6557 2853. Where the report contains research analyses or research reports from a foreign research house and if the recipient of such research analyses or research reports is not an accredited investor, expert investor, institutional investor or an ex-accredited investor, IFPL accepts legal responsibility for the contents of such analyses or reports to such persons only to the extent as required by law. Please note that only certain security(ies) herein are available to all investors, while the rest are only available for certain persons to invest in, such as Accredited Investors (as defined in the Securities and Futures Act) or one who invests at least S$200,000 (or its equivalent currency) per transaction. To qualify as an Accredited Investor, one needs to submit a declaration form and certain relevant supporting documents, according to iFAST’s prevailing policies and procedures.

Please read our full disclaimers on the website at ( https://secure.fundsupermart.com/fsmone/policies/328125/investment-account-terms-&-conditions).

iFAST Financial Pte Ltd (IFPL) (registered address: 10 Collyer Quay #26-01 Ocean Financial Centre Singapore 049315, Telephone: 6557 2000) holds the Financial Advisers Licence issued by the Monetary Authority of Singapore ('MAS') to conduct regulated activities of advising on securities, marketing of collective investment schemes and arranging of any contract of insurance in respect of life policies, other than a contract of reinsurance and the Capital Markets Services Licence issued by the MAS to conduct regulated activities of dealing in securities and providing custodial services for securities. While IFPL has made every effort to ensure the independence of the report's contents, IFPL's nature of business is such that IFPL and its connected and associated entities together with their respective directors, officers and staff may be involved in providing dealing or investment-related services in the abovementioned securities, and have taken or may take positions in the securities mentioned in this report, and may also act as the principal for any buy or sell trades.


Ways to Invest with FSM Global
Why FSM Global
Don't have an account with us?
Open an account here
Need Financial Advice?
Make an appointment
Related Articles More

We use cookies If you close this message or continue to use this site, you will consent to the use of Cookies, unless you choose to disable them. Click on our Privacy Policy to understand more.